Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{juUGlEPTB;MD6wNFA1PThibl2= NWC2eY1FW0GQR1XS
ES4 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H3SWlEPTB;MD6wNFA3PTNibl2= M{W5PHNCVkeHUh?=
ACHN M2Xhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nMfGlEPTB;MD6wNFA5QDdibl2= M3frcnNCVkeHUh?=
KYSE-510 NFr0OZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrWTWM2OD1yLkCwNFk4PSCwTR?= NEG3c|lUSU6JRWK=
EW-7 NYS4VI5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMECyOVghdk1? NWK4cIpoW0GQR1XS
BFTC-905 M{\Mcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEC1NVUhdk1? M2nzRnNCVkeHUh?=
KE-37 NXPYbVloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTpN|ZOUUN3ME2wMlAxPTZzIH7N NUm3XoVrW0GQR1XS
SBC-5 M4PNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXSUIlKUUN3ME2wMlAxPTdibl2= MVfTRW5ITVJ?
NKM-1 M{\pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5emlEPTB;MD6wNFcxQSCwTR?= MUXTRW5ITVJ?
RH-1 M1LlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W1UGlEPTB;MD6wNFcyQCCwTR?= NHqzUYpUSU6JRWK=
ALL-PO NIriWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\jNo9KSzVyPUCuNFA5OyCwTR?= MV;TRW5ITVJ?
QIMR-WIL MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ZV4tYUUN3ME2wMlAxQDl2IH7N NUDNRoc4W0GQR1XS
A375 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnYU|Y4UUN3ME2wMlAxQTl3IH7N NWnXRXFGW0GQR1XS
SIG-M5 NUftOWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7ybmY6UUN3ME2wMlAyODRibl2= MXXTRW5ITVJ?
KGN MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7jTWM2OD1yLkCxNFghdk1? Mo\GV2FPT0WU
EW-13 NEL1eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rmSWlEPTB;MD6wNVEzKG6P MX\TRW5ITVJ?
NCI-SNU-1 NULvWmRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPtT5RuUUN3ME2wMlAyPiCwTR?= MnnrV2FPT0WU
PSN1 NWTsN|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMEG2OUBvVQ>? NWXDXmJ4W0GQR1XS
HUTU-80 M3rsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD4V3psUUN3ME2wMlAyPjZibl2= M2fJfHNCVkeHUh?=
EW-16 M2m0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj4TWM2OD1yLkCyN{BvVQ>? M1LIbXNCVkeHUh?=
786-0 NE\XOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLGTWM2OD1yLkCyN{BvVQ>? NF[xSJFUSU6JRWK=
ES1 M1HZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DZPGlEPTB;MD6wNlY5KG6P NHrQO4RUSU6JRWK=
RKO MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvHfWVEUUN3ME2wMlAzPzlibl2= NGf5W4tUSU6JRWK=
ESS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnoPJlKSzVyPUCuNFI5PiCwTR?= NUPPWHE1W0GQR1XS
SK-UT-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEK5O{BvVQ>? MU\TRW5ITVJ?
LB2241-RCC M4PXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjhZ2FCUUN3ME2wMlA{OThibl2= MVLTRW5ITVJ?
CHL-1 M1jyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPHTWM2OD1yLkCzNlQhdk1? MVjTRW5ITVJ?
SW1783 M1Lqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\sNWlEPTB;MD6wN|M3KG6P MmDiV2FPT0WU
MEL-JUSO M3u3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzqPJd7UUN3ME2wMlA{QTFibl2= MVjTRW5ITVJ?
HT-29 M4i4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPnTWM2OD1yLkC0NVMhdk1? NILkNGhUSU6JRWK=
SNG-M NELJR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljjTWM2OD1yLkC0NlUhdk1? MULTRW5ITVJ?
TE-15 NH36WHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjMVnk1UUN3ME2wMlA1PjRibl2= MU\TRW5ITVJ?
HOS MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rTWM2OD1yLkC0PEBvVQ>? M4LOeXNCVkeHUh?=
BB65-RCC NYfVT5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe5dlNOUUN3ME2wMlA2OTJibl2= M3XtcHNCVkeHUh?=
HCE-4 NFu4d5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm3VYxDUUN3ME2wMlA2Ojhibl2= NHvYWYVUSU6JRWK=
MHH-ES-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\uXoVnUUN3ME2wMlA2OzFibl2= NYrDXG5zW0GQR1XS
RPMI-7951 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxfnBKSzVyPUCuNFU1OSCwTR?= MmHsV2FPT0WU
IST-SL2 M37IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljOTWM2OD1yLkC1PFQhdk1? M4XJVXNCVkeHUh?=
CMK M1PWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT2d5BKSzVyPUCuNFU5PiCwTR?= M1T2OHNCVkeHUh?=
GR-ST NFLoUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu3TWM2OD1yLkC1PVUhdk1? NF\RNGpUSU6JRWK=
NALM-6 M{HTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULzXoliUUN3ME2wMlA3OjJibl2= MXrTRW5ITVJ?
RPMI-6666 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;LTWM2OD1yLkC2OVIhdk1? NH3FRmRUSU6JRWK=
LC-2-ad MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX74cGhJUUN3ME2wMlA3PTNibl2= Mn[2V2FPT0WU
ARH-77 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[5fmlEPTB;MD6wO|EyKG6P M2HqT3NCVkeHUh?=
IST-MEL1 NIm1bXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7N[IpyUUN3ME2wMlA4OjZibl2= NYq0WYZ5W0GQR1XS
SW1710 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjYOY1KSzVyPUCuNFc2OSCwTR?= M1jKZ3NCVkeHUh?=
DEL M13xZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLtTWM2OD1yLkC4PFchdk1? NX7jZ2lZW0GQR1XS
AGS MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjMS2tKSzVyPUCuNFkxOiCwTR?= MlrLV2FPT0WU
NCI-H2122 NVPDWVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrhOphKSzVyPUCuNFk1PiCwTR?= NYrScFJ[W0GQR1XS
HSC-4 NVXYUXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDnN4JKSzVyPUCuNVAzKG6P M{THfXNCVkeHUh?=
AM-38 M2PmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMUKxJI5O MV;TRW5ITVJ?
769-P M32xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzYN4RDUUN3ME2wMlEzOyCwTR?= MXvTRW5ITVJ?
RT-112 NFzpRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:3PJBKSzVyPUCuNVI4KG6P MWXTRW5ITVJ?
MCF7 NIT1UWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\iWGlEPTB;MD6xN|Yhdk1? M2fYcnNCVkeHUh?=
IGROV-1 M2\5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULW[mJkUUN3ME2wMlE1PSCwTR?= NVeyb5JlW0GQR1XS
OCI-AML2 M3vCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm3UJltUUN3ME2wMlE1PyCwTR?= MULTRW5ITVJ?
NCI-H1299 M{TqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPUR3c{UUN3ME2wMlE2PyCwTR?= MlrGV2FPT0WU
A431 NHu0e4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUizJI5O M1nOcHNCVkeHUh?=
SW982 NYHxOWJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK0cYtKSzVyPUCuNlE{KG6P MmPXV2FPT0WU
BB30-HNC NE[2NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LLZWlEPTB;MD6yN|Ehdk1? M1zIXnNCVkeHUh?=
ACN MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\QemlEPTB;MD6yOFQhdk1? Mn\LV2FPT0WU
647-V M1rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrH[5RKSzVyPUCuNlQ5KG6P M{jzT3NCVkeHUh?=
SK-PN-DW NFe4NlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL2TWM2OD1yLkK2OkBvVQ>? NGTYTG5USU6JRWK=
LCLC-97TM1 M2DMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e1SmlEPTB;MD6yOlchdk1? NF\2OHlUSU6JRWK=
LB1047-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMk[5JI5O MmC5V2FPT0WU
A2780 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPmTWM2OD1yLkK3JI5O NFf3cGxUSU6JRWK=
C-33-A NYjyZ4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3LTWM2OD1yLkK3N{BvVQ>? MYLTRW5ITVJ?
NCI-H2228 M2jZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwM{G0JI5O M4DE[HNCVkeHUh?=
TE-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LkNmlEPTB;MD6zNVYhdk1? NXXEXGtTW0GQR1XS
HC-1 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\HT|VmUUN3ME2wMlMzPyCwTR?= MljwV2FPT0WU
SK-MES-1 MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTZXIxKSzVyPUCuN|I5KG6P Mkm3V2FPT0WU
NCI-H1355 M2D3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXle4NFUUN3ME2wMlM5OSCwTR?= MVTTRW5ITVJ?
YKG-1 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWxTWM2OD1yLkSxPUBvVQ>? NXrMVpUzW0GQR1XS
RS4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj0UYJKSzVyPUCuOFM{KG6P M4frWnNCVkeHUh?=
Daoy NHXrOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\ZWGxKSzVyPUCuOFU3KG6P MWDTRW5ITVJ?
A3-KAW MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v3OWlEPTB;MD61OVEhdk1? NEfNVpdUSU6JRWK=
SK-MEL-30 NUfGWJE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLzWnlKSzVyPUCuOVU1KG6P Mnv5V2FPT0WU
U031 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnVTWM2OD1yLkW2OUBvVQ>? M4rLXXNCVkeHUh?=
SK-LMS-1 NETEb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknLTWM2OD1yLkW3PEBvVQ>? NXG4[2pJW0GQR1XS
ES6 NF;mNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDufYJKSzVyPUCuOVg3KG6P NVLEfnR6W0GQR1XS
EoL-1-cell Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXqRmR5UUN3ME2wMlYyPiCwTR?= MoO1V2FPT0WU
NCI-H2009 M{jjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\xTWM2OD1yLk[xPUBvVQ>? MoXVV2FPT0WU
A4-Fuk MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULLOFFIUUN3ME2wMlYzPiCwTR?= NVjNeHlNW0GQR1XS
KYSE-270 M1SyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\xVmlEPTB;MD62N|Qhdk1? M{P3S3NCVkeHUh?=
SK-LU-1 NXHBdW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInkN2NKSzVyPUCuOlU2KG6P M4XQbnNCVkeHUh?=
SW872 M3rmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[0UGlEPTB;MD63OlUhdk1? MmnQV2FPT0WU
ES8 NHPsUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP5TWM2OD1yLke4JI5O NEjjUJZUSU6JRWK=
G-402 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy5O2w1UUN3ME2wMlc5PCCwTR?= MU\TRW5ITVJ?
ATN-1 NXrGXVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr2TWM2OD1yLkiwO{BvVQ>? MVXTRW5ITVJ?
DoTc2-4510 NYrkSJBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOUCxJI5O NFTVNGRUSU6JRWK=
MES-SA NVexe4J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n3R2lEPTB;MD65NFUhdk1? NV3wOI5TW0GQR1XS
SF268 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XGcWlEPTB;MD65Nlchdk1? MVnTRW5ITVJ?
SF539 MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fTdmlEPTB;MT6wNkBvVQ>? NEPGUlVUSU6JRWK=
NB69 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf6TWM2OD1zLkC1JI5O M2XqbHNCVkeHUh?=
8505C NHS2SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37WfGlEPTB;MT6wOkBvVQ>? M1n0[XNCVkeHUh?=
CAL-12T M2XreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XXWGlEPTB;MT6wPEBvVQ>? NVf6O|lrW0GQR1XS
BHY M3LOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPH[lZEUUN3ME2xMlE1KG6P MlPkV2FPT0WU
LB647-SCLC NUn0eXpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M134c2lEPTB;MT6xPEBvVQ>? NG\sd4NUSU6JRWK=
CAL-62 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3vNIhKSzVyPUGuNlIhdk1? M4ThW3NCVkeHUh?=
MEG-01 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rDZWlEPTB;MT6yO{BvVQ>? MX7TRW5ITVJ?
MG-63 NY\N[lB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPlTWM2OD1zLkOzJI5O M1fibHNCVkeHUh?=
SW620 NFnLOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXB[WpyUUN3ME2xMlM2KG6P NWjUUJVOW0GQR1XS
A388 NEHtU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXXcIVKSzVyPUGuN|Yhdk1? MnPNV2FPT0WU
BCPAP MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXhVYI3UUN3ME2xMlQ2KG6P MoT6V2FPT0WU
P30-OHK MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLVTWM2OD1zLkS2JI5O MnfJV2FPT0WU
Ca9-22 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LUSGlEPTB;MT61OEBvVQ>? MYLTRW5ITVJ?
VMRC-RCZ MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3DWWZKSzVyPUGuOVQhdk1? NFe0S5VUSU6JRWK=
LOXIMVI NVP5NmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXHTWM2OD1zLk[gcm0> MX3TRW5ITVJ?
L-540 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\WbWdDUUN3ME2xMlYhdk1? MW\TRW5ITVJ?
NTERA-S-cl-D1 M4fGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwNkSgcm0> MXLTRW5ITVJ?
MFH-ino NHP3N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjjTWM2OD1zLk[2JI5O NH7kUHhUSU6JRWK=
Calu-6 NFLidoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmU45KSzVyPUGuO|Mhdk1? MlPLV2FPT0WU
HEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H6NWlEPTB;MT63PUBvVQ>? MlnGV2FPT0WU
CAL-33 NEnWe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33i[mlEPTB;MT64PUBvVQ>? NWLBNHhoW0GQR1XS
HSC-3 M1XuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjycY9mUUN3ME2xMlkyKG6P MUTTRW5ITVJ?
KU812 M2rIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnEbXNOUUN3ME2xMlkyKG6P NYrjOGx2W0GQR1XS
EB2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrhTWM2OD1{LkCxJI5O NX:4UWh5W0GQR1XS
SR Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPPPGZKSzVyPUKuNVIhdk1? MkHvV2FPT0WU
NCI-H2087 NYe5clBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q5XGlEPTB;Mj6xOEBvVQ>? MWDTRW5ITVJ?
H4 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjDU|hYUUN3ME2yMlE5KG6P M1fXe3NCVkeHUh?=
EW-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDaSGFKSzVyPUKuNlIhdk1? M{n6fnNCVkeHUh?=
MC-IXC NVTTXYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2noNWlEPTB;Mj6yOkBvVQ>? MXfTRW5ITVJ?
NCI-H727 NYLLTFh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjwUGtKSzVyPUKuOVEhdk1? Mn3jV2FPT0WU
MRK-nu-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL2TWM2OD1{LkW3JI5O MVLTRW5ITVJ?
COLO-668 M3PBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH2N4VKSzVyPUKuOlYhdk1? MVrTRW5ITVJ?
CGTH-W-1 NGK5UHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrV[2dnUUN3ME2yMlczKG6P MXHTRW5ITVJ?
CHP-212 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzETWM2OD1{Lke1JI5O NIrIVmlUSU6JRWK=
GI-1 NXXufGlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfKSGtPUUN3ME2yMlc3KG6P MmHIV2FPT0WU
HCC1806 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\BS4dKSzVyPUKuPVEhdk1? MkG4V2FPT0WU
HLE MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNibl2= MnvrV2FPT0WU
HSC-2 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS2cpBKSzVyPUOuNFMhdk1? NGnY[GlUSU6JRWK=
DMS-273 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNwMEegcm0> M4DOS3NCVkeHUh?=
DU-4475 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHMTWM2OD1|LkG0JI5O NVfuTZdCW0GQR1XS
LXF-289 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5SZAxUUN3ME2zMlMyKG6P M{PpSnNCVkeHUh?=
PANC-03-27 NHXsWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv6bFNKSzVyPUOuOVEhdk1? MmmzV2FPT0WU
GAMG M3j6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonMTWM2OD1|Lke0JI5O MV;TRW5ITVJ?
NCI-H522 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qxVGlEPTB;ND6zOEBvVQ>? M1jTe3NCVkeHUh?=
SW626 NHfMZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT1SpdvUUN3ME20MlQ3KG6P MknGV2FPT0WU
HT-144 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK1TWM2OD12LkmyJI5O MmfqV2FPT0WU
MEL-HO MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwMU[gcm0> NH22UYNUSU6JRWK=
BE-13 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwMkGgcm0> NUHCV5JmW0GQR1XS
VA-ES-BJ NF3QO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PXTWlEPTB;NT6yOkBvVQ>? MoLEV2FPT0WU
NCI-H441 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwNjDuUS=> MnXpV2FPT0WU
KP-4 NXO5cHJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXYd5NxUUN3ME21MlYyKG6P NYXGfVJMW0GQR1XS
LoVo M2\hNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[2XGlEPTB;NT63NUBvVQ>? MknCV2FPT0WU
HT-1080 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPJTWM2OD13LkizJI5O NULlPYY6W0GQR1XS
GB-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTzdJA{UUN3ME21Mlg1KG6P NHvnZpNUSU6JRWK=
IA-LM NGDo[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi5dWV3UUN3ME21MlkyKG6P MXjTRW5ITVJ?
8-MG-BA NWC4bXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nxcWlEPTB;NT65N{BvVQ>? NEfpcXpUSU6JRWK=
SK-HEP-1 NGHnN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm2TWM2OD14LkG0JI5O NWH0elhFW0GQR1XS
697 NVrsSlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33sfWlEPTB;Nj6yOUBvVQ>? MkDJV2FPT0WU
KYSE-450 NWrVSZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGyemVKSzVyPU[uN|Ihdk1? MkLXV2FPT0WU
HCC2998 NXmzXoZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTZwM{Sgcm0> NXnJXYpDW0GQR1XS
HD-MY-Z NFvxVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf6OnhKSzVyPU[uOlghdk1? MV7TRW5ITVJ?
OS-RC-2 M4rIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD14Lk[4JI5O NYjwRlg6W0GQR1XS
SF126 NF63OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTdwMEWgcm0> NFjPUoVUSU6JRWK=
Ca-Ski NVz5V3E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\lTWM2OD15LkC5JI5O NEmxdmRUSU6JRWK=
NCI-H358 NV\aZVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HGSmlEPTB;Nz6xOkBvVQ>? NWCzUIFjW0GQR1XS
J82 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLrTWM2OD15LkSxJI5O MnvuV2FPT0WU
NCI-H2342 M4flSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzGbJlZUUN3ME23MlY{KG6P NILYZ5dUSU6JRWK=
OVCAR-8 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7ON29KSzVyPUeuPUBvVQ>? M3SxfHNCVkeHUh?=
TE-8 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HjNmlEPTB;ODDuUS=> NFfudpVUSU6JRWK=
ETK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2izfmlEPTB;OD6wPEBvVQ>? NVTLNIlEW0GQR1XS
HAL-01 NWXR[mFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmxbWNoUUN3ME24MlIhdk1? NV:2TpcyW0GQR1XS
KYSE-150 NVvDcIVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW1TWM2OD16LkS3JI5O MmjGV2FPT0WU
NCI-H810 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTJTWM2OD16LkW2JI5O MWPTRW5ITVJ?
ONS-76 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRThwNkigcm0> MmPkV2FPT0WU
NMC-G1 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nONWlEPTB;OD63OkBvVQ>? MkLzV2FPT0WU
C3A M{H2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXPdYhKSzVyPUiuPFQhdk1? MUTTRW5ITVJ?
PA-1 NX;YSHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[1emlEPTB;OD65PUBvVQ>? NY\zdnpuW0GQR1XS
SH-4 NYDQXlZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTlwMEKgcm0> NIWzVI9USU6JRWK=
EFO-27 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPBTWM2OD17LkC1JI5O MkTBV2FPT0WU
CAPAN-1 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz2TWM2OD17LkKzJI5O NVvEcVRSW0GQR1XS
DU-145 NFz3WotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfMV3V2UUN3ME25MlI6KG6P MkHYV2FPT0WU
A101D NYC5UY1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\GOJdKSzVyPUmuN|chdk1? M4q2XHNCVkeHUh?=
ST486 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTlwNEGgcm0> Ml7HV2FPT0WU
NCI-H1437 NFrRO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrtTWM2OD17LkSyJI5O NWHsbmxlW0GQR1XS
HGC-27 NVzKU5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ZTWM2OD17Lk[gcm0> MmHrV2FPT0WU
8305C MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTlwNkSgcm0> NV;ISXY6W0GQR1XS
OCUB-M M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXVe4VEUUN3ME2xNE4xOyCwTR?= NXPieFJJW0GQR1XS
COLO-679 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjqVFh3UUN3ME2xNE4xPyCwTR?= Mm\6V2FPT0WU
Detroit562 M17VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXnXI1KSzVyPUGwMlQzKG6P NHfkXZpUSU6JRWK=
A204 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFzLkG2JI5O MmjXV2FPT0WU
NCI-H1734 NYK1b41mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXKTWM2OD1zMT6yPUBvVQ>? Mn:xV2FPT0WU
MC-CAR NWW4[lhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ryN2lEPTB;MUGuOVghdk1? M3[3S3NCVkeHUh?=
NCI-H2170 NWTpRoJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrrN5dqUUN3ME2xNU46PyCwTR?= NWPi[mwxW0GQR1XS
NCI-SNU-5 NYn2fY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXvTWM2OD1zMj6xN{BvVQ>? M2Xt[3NCVkeHUh?=
HCE-T NXjibYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HoSWlEPTB;MUKuOFIhdk1? NUH2cYJ7W0GQR1XS
KYSE-180 NVznXXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nnc2lEPTB;MUKuPFEhdk1? MWrTRW5ITVJ?
C8166 M4nKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD1zMz6wPEBvVQ>? MYDTRW5ITVJ?
NCI-H460 NFjXRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmWm5qUUN3ME2xN{42PCCwTR?= M4TVbXNCVkeHUh?=
SNU-449 M1;kVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHNTWM2OD1zMz63O{BvVQ>? MlHXV2FPT0WU
MDA-MB-468 M2Xm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorUTWM2OD1zND6xNkBvVQ>? NXvZXVc4W0GQR1XS
COR-L23 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\pfGlEPTB;MUSuNVMhdk1? MYTTRW5ITVJ?
CTV-1 NXnzVnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLPTWM2OD1zND6xOEBvVQ>? MXfTRW5ITVJ?
BL-41 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3aem9KSzVyPUG0MlM4KG6P M{fyNHNCVkeHUh?=
IGR-1 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OzeWlEPTB;MUSuOFIhdk1? MYXTRW5ITVJ?
TK10 NYfwXm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOSVV1UUN3ME2xOE41QSCwTR?= NXjJXZppW0GQR1XS
REH MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPISIRHUUN3ME2xOE42OSCwTR?= M3W2fHNCVkeHUh?=
LU-139 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF2LkW5JI5O NUfMS|BqW0GQR1XS
KP-N-YS Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH24bllKSzVyPUG0Mlk4KG6P NEjqW5lUSU6JRWK=
PANC-10-05 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxXGNNUUN3ME2xOU4{QCCwTR?= Mn:wV2FPT0WU
HL-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF3Lk[5JI5O NHy4eHNUSU6JRWK=
T84 NUjK[IptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rZVWlEPTB;MUWuPVYhdk1? M4fheXNCVkeHUh?=
RPMI-8226 NUXyRYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD1zNj6wNkBvVQ>? M3\4S3NCVkeHUh?=
UM-UC-3 M{fJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF4LkG2JI5O NYq3[VFVW0GQR1XS
TE-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XWVGlEPTB;MU[uNlEhdk1? NYfEZ5JoW0GQR1XS
CAL-148 NYrzTopPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj0TWM2OD1zNz6yN{BvVQ>? NYH2fmJQW0GQR1XS
BV-173 M2PofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF5LkK3JI5O MmG5V2FPT0WU
Calu-3 NYPCSFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TVdmlEPTB;MUeuNlkhdk1? NH;qOpVUSU6JRWK=
RPMI-2650 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDUTWM2OD1zNz61PUBvVQ>? NETkem5USU6JRWK=
MKN45 NIPNU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTxTWM2OD1zNz63N{BvVQ>? MVvTRW5ITVJ?
NUGC-3 Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjNTWM2OD1zOD6zOEBvVQ>? MlnDV2FPT0WU
NCI-H520 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rnfGlEPTB;MUiuO|chdk1? MofBV2FPT0WU
CCRF-CEM NEPF[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XCN2lEPTB;MUiuPFUhdk1? MonnV2FPT0WU
NCI-H2405 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPPdIU2UUN3ME2xPU4yKG6P NWS0dGhiW0GQR1XS
ES7 NHP4WZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5XWlEPTB;MUmuO|Yhdk1? MkT1V2FPT0WU
BPH-1 NHLzUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJyLkK4JI5O NU\HW5RxW0GQR1XS
SAS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[3bmlEPTB;MkCuOUBvVQ>? NIDUVZFUSU6JRWK=
HuCCT1 NWC4dFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\FTWM2OD1{MD61PEBvVQ>? NUHkd5pkW0GQR1XS
LOUCY NWHYNFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPnOVhKSzVyPUKwMlY3KG6P NEO0UJZUSU6JRWK=
NCI-H292 NHXZZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJyLke5JI5O MnT5V2FPT0WU
G-361 Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DyNGlEPTB;MkGuNFchdk1? M{PPOHNCVkeHUh?=
M059J NYGxNml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XlO2lEPTB;MkGuNFghdk1? NUj5dW9WW0GQR1XS
NCI-H1651 NXKyTYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfFVYVKSzVyPUKxMlEyKG6P MXfTRW5ITVJ?
KALS-1 NUXNNHV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\sR|VKSzVyPUKxMlM6KG6P MVTTRW5ITVJ?
DJM-1 M3[zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPwc4VMUUN3ME2yNU42QSCwTR?= M2GwPHNCVkeHUh?=
AU565 M4\H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJzLkizJI5O M4XyXHNCVkeHUh?=
HCC38 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TrR2lEPTB;MkGuPVUhdk1? NUTlboRxW0GQR1XS
U251 M4H4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfEfW5kUUN3ME2yNk4zPyCwTR?= M2OzU3NCVkeHUh?=
ABC-1 M1S1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPIW3VXUUN3ME2yNk43PSCwTR?= M3;vOnNCVkeHUh?=
SK-NEP-1 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLw[IRkUUN3ME2yNk46OyCwTR?= MV;TRW5ITVJ?
CESS M2m0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7LTGJlUUN3ME2yN{4yQSCwTR?= MVXTRW5ITVJ?
MIA-PaCa-2 NVrZfmp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PPR2lEPTB;MkOuN|Yhdk1? Mmn1V2FPT0WU
SUP-T1 M2LzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jOTmlEPTB;MkOuOFchdk1? NGTkUG1USU6JRWK=
L-428 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;qVVVKSzVyPUKzMlYzKG6P M3nQ[3NCVkeHUh?=
SW954 M4Lnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\mZpZKSzVyPUKzMlY5KG6P M3TY[XNCVkeHUh?=
HO-1-N-1 NIDwfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ|Lke3JI5O MYHTRW5ITVJ?
CHP-126 M13FfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nqdWlEPTB;MkSuNVQhdk1? M4D2NXNCVkeHUh?=
HMV-II MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fJN2lEPTB;MkSuN|Qhdk1? M1zRRXNCVkeHUh?=
NB10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjpPVN6UUN3ME2yOE4{PyCwTR?= NH3jeWZUSU6JRWK=
A172 NX;BTJo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ2LkexJI5O NFLRZlFUSU6JRWK=
MONO-MAC-6 NUTobZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPCTWM2OD1{ND64OEBvVQ>? MkjNV2FPT0WU
NCI-H1650 M37BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ3LkSgcm0> M{TLSXNCVkeHUh?=
NH-12 NIHkW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5co1KSzVyPUK1MlUhdk1? NFLwWYNUSU6JRWK=
ML-2 NI\q[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrpTWM2OD1{NT63OEBvVQ>? MUXTRW5ITVJ?
MZ2-MEL MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHINIY1UUN3ME2yOk4zOiCwTR?= NUDleXdiW0GQR1XS
COLO-684 NYHMN442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTBTWM2OD1{Nj60NUBvVQ>? NUPr[YNsW0GQR1XS
HuP-T4 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\PXplKSzVyPUK3MlMhdk1? NWn1eGRWW0GQR1XS
SW837 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXuN|dnUUN3ME2yO{43OiCwTR?= NFOxNYpUSU6JRWK=
MDA-MB-231 NFjYT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTzUJFJUUN3ME2yO{44QCCwTR?= NVzZT3k6W0GQR1XS
KYSE-140 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrtcWJKSzVyPUK3MlkyKG6P M3:wdnNCVkeHUh?=
NOMO-1 NYHJN49FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjhTWM2OD1{OD62PEBvVQ>? NFTPdWxUSU6JRWK=
GP5d M1zON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ6LkeyJI5O M1LzSHNCVkeHUh?=
COR-L105 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7lTWM2OD1{OT60NkBvVQ>? MXfTRW5ITVJ?
LS-411N MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7BXZJKSzVyPUK5Mlg5KG6P NULHS5cyW0GQR1XS
NY MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\MdGlEPTB;M{CuNVghdk1? NV\GTJdGW0GQR1XS
NCI-H2030 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfQR45KSzVyPUOwMlQ2KG6P NYGwXY16W0GQR1XS
CCF-STTG1 NVjLUJVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XFPWlEPTB;M{GuOFIhdk1? M3fmVHNCVkeHUh?=
NCI-H1703 NFPXPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHpTWM2OD1|MT63PEBvVQ>? MWHTRW5ITVJ?
TUR M4rqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDsTWM2OD1|Mj6wN{BvVQ>? NFqwOoJUSU6JRWK=
NOS-1 M4\S[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37JeGlEPTB;M{KuOFQhdk1? MnvEV2FPT0WU
A2058 M4\Jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN{LkizJI5O NXHrNFhKW0GQR1XS
LCLC-103H NX3GWYY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOxTWM2OD1|Mz6yOUBvVQ>? M1;0WnNCVkeHUh?=
NCI-H510A M{PqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfhRplLUUN3ME2zN{4zPyCwTR?= M{O1c3NCVkeHUh?=
BC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDieWpkUUN3ME2zN{44PyCwTR?= MmWyV2FPT0WU
SK-CO-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nkfWlEPTB;M{SuNFEhdk1? MkjtV2FPT0WU
A673 M{GzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXQdY9KSzVyPUO0MlE4KG6P NXnCPHJxW0GQR1XS
VM-CUB-1 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT2WG5KSzVyPUO0MlY6KG6P MlK2V2FPT0WU
HH MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[2XmdKSzVyPUO1MlA3KG6P NH;4cJlUSU6JRWK=
CAL-27 NX7B[mtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO4NZJ5UUN3ME2zOU4yPiCwTR?= NV\oeYM5W0GQR1XS
NEC8 NXjEN24zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DYWmlEPTB;M{WuN|chdk1? MYfTRW5ITVJ?
BxPC-3 NEjKUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT2TWM2OD1|Nj65NUBvVQ>? MYnTRW5ITVJ?
SNB75 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zDe2lEPTB;M{euNlQhdk1? M3nsPHNCVkeHUh?=
NB13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN6LkKzJI5O NYLHWlhXW0GQR1XS
SK-OV-3 NELGOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LCdGlEPTB;M{iuO|Qhdk1? M2Psc3NCVkeHUh?=
ME-180 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHQTWM2OD1|OD64JI5O NGLKcGhUSU6JRWK=
JiyoyeP-2003 M33sOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH6UpJ3UUN3ME2zPU4{QCCwTR?= MVjTRW5ITVJ?
LU-134-A MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorETWM2OD12MD6wNkBvVQ>? M3:xVnNCVkeHUh?=
LS-123 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\sTWM2OD12MD6yPEBvVQ>? NUPye49YW0GQR1XS
COLO-800 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:3PWlEPTB;NECuOVYhdk1? MXLTRW5ITVJ?
LB831-BLC NHnHdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX70W5ZWUUN3ME20NU45PSCwTR?= MojTV2FPT0WU
NCI-H747 M3nqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPvTpdvUUN3ME20Nk4zQCCwTR?= MX7TRW5ITVJ?
MZ7-mel MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvTWM2OD12Mj62OkBvVQ>? NXXWdYdjW0GQR1XS
GT3TKB MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;3TpVPUUN3ME20Nk44OiCwTR?= MV7TRW5ITVJ?
MOLT-16 NXTZcWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR|LkC1JI5O NWC2VpUyW0GQR1XS
23132-87 M4\Cc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfVZ5doUUN3ME20N{4xPSCwTR?= M3S1VXNCVkeHUh?=
PF-382 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD12ND6yNkBvVQ>? NUez[Gg{W0GQR1XS
ES3 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPJOXFKSzVyPUS0MlYhdk1? Mnz3V2FPT0WU
SW756 M3O1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR3LkG0JI5O NETFSZVUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
water (warmed)
いい結果が出るために、混じった後、直ちに使うと推めます。
52mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

Related Antibodies

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID